US 11,702,421 B2
Substituted pyridines as irreversible inhibitors of menin-MLL interaction
Thomas Butler, Redwood City, CA (US); Jim Palmer, Warrandyte (AU); Ravi Upasani, San Jose, CA (US); Matthew Welsch, New Haven, CT (US); Sridhar Vempati, Edison, NJ (US); Brendan Kelly, Castlecomer (IE); and Edward Painter, Chappaqua, NY (US)
Assigned to BIOMEA FUSION, LLC, Redwood City, CA (US)
Filed by BIOMEA FUSION, LLC, Redwood City, CA (US)
Filed on Jun. 18, 2021, as Appl. No. 17/352,146.
Application 17/352,146 is a continuation of application No. 16/732,226, filed on Dec. 31, 2019, granted, now 11,084,825, issued on Aug. 10, 2021.
Claims priority of provisional application 62/786,842, filed on Dec. 31, 2018.
Prior Publication US 2022/0169627 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); C07D 487/04 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 401/04 (2013.01); C07D 401/06 (2013.01)] 4 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.